Obsessive-compulsive disorder in general hospital outpatients: Prevalence, correlates, and comorbidity in Lanzhou, China

Ma, Lijun; Zhang, Tao; SiYong, Huang; Suwen, Wei; Yuan, Xiaoxuan; Guo, Yichen; Zhang, Caiyun; Yan, Binbin

doi:10.1111/appy.12113

Cited by 7 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epidemiologic studies have estimated the prevalence of OCD is 2% in the general population, up to 4% in general psychiatric inpatient setting. [9,10] The recent literature has suggested that the frequency of prominent OCS in schizophrenia is around 25% and 11%-21% of persons with bipolar disorder at some time during their bipolar disorder. [11,12] In this study, the overall prevalence of OCS in the study sample was 30.5%, the prevalence of OCS in schizophrenia subjects was 29.26%, and 33% in BPAD subjects.…”

Section: Discussionmentioning

confidence: 99%

Prevalence and Pattern of Olanzapine Emergent Obsessive–Compulsive Symptoms: A Cross-sectional Study

Mishra,

Singh,

Kishore

et al. 2023

Apollo Medicine

View full text Add to dashboard Cite

Objective: Olanzapine is an atypical antipsychotic medication and known for metabolic side effects but olanzapine-induced obsessive–compulsive symptoms are another important behavioral side effects which are less studied and only a few case reports reported these side effects. This study aims to estimate the prevalence and pattern of olanzapine-induced obsessive–compulsive symptoms in schizophrenia and bipolar affective disorders (BPADs). Methods: Subjects were recruited from psychiatry outpatient department. Subjects with schizophrenia (n = 41) and BPAD (n = 18) taking olanzapine at least more than 6 months were evaluated for clinical profile and the presence of obsession and compulsion symptoms by means of Yale-Brown Obsessive–Compulsive Symptom (YBOCS) checklist scale and data were collected on the structured format. Results: Eighteen (30.5%) of the 59 patients met YBOCS checklist scale for both obsessive–compulsive symptoms among subjects with schizophrenia and BPAD subjects. The mean duration of olanzapine intake was 2 years and the mean dose of olanzapine was 12.5 ± 5.21 mg in obsessive–compulsive symptoms (OCSs) present subjects and the mean dose was 13.78 ± 5.21 mg in subjects not having OCSs. Contamination was the most common obsession and checking was the most common compulsion. Conclusions: These findings suggest that obsessive–compulsive symptoms occur in a substantial percentage of patients taking olanzapine in schizophrenia and BPAD and most of the subjects had more than one OCS.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence and Pattern of Olanzapine Emergent Obsessive–Compulsive Symptoms: A Cross-sectional Study

Mishra,

Singh,

Kishore

et al. 2023

Apollo Medicine

View full text Add to dashboard Cite

show abstract

Transcutaneous electrical acupoint stimulation as an adjunct therapy for obsessive-compulsive disorder: A randomized controlled study

Feng

Zhang

Zhu

et al. 2016

Journal of Psychiatric Research

View full text Add to dashboard Cite

Background: Transcutaneous electrical acupoint stimulation (TEAS) is thought to have potential to treat obsessive-compulsive disorder (OCD).Objective: The purpose of this study was to determine whether adding TEAS to cognitive behavioral therapy (CBT) and clomipramine would improve the efficacy of these conventional treatments in OCD.Methods: In this randomized controlled trial, 360 OCD patients were assigned to receive TEAS combined with CBT plus clomipramine (Group A, n = 120), TEAS combined with CBT plus placebo (Group B, n = 120), and simulated (placebo) TEAS combined with CBT plus clomipramine (Group C, n = 120) for 12 weeks. The primary outcome was measured using the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS).Results: OCD symptoms in all patients reduced over time, however Groups A and B had a significantly greater reduction in Y-BOCS total score and the subscale for obsession and compulsion between week 2 and week 12 compared to Group C. Groups A and B had similar scores on these measures. Both groups had significantly higher rates of clinical response than Group C (88.3% and 81.7% vs. 67.5%, respectively, p < 0.001); and higher rates of remission (30.0% and 22.5% vs. 9.2%, respectively, p < 0.001).Group B experienced fewer adverse events than the other two groups.Conclusions: TEAS enhances the efficacy of conventional OCD interventions and avoids the adverse effects associated with conventional pharmacological treatment. It can be considered as an effective adjunct intervention for OCD.

show abstract

Systematic review of environmental risk factors for Obsessive-Compulsive Disorder: A proposed roadmap from association to causation

Brander

Pérez-Vigil

Larsson

et al. 2016

Neuroscience & Biobehavioral Reviews

120

View full text Add to dashboard Cite

Obsessive-compulsive disorder in general hospital outpatients: Prevalence, correlates, and comorbidity in Lanzhou, China

Cited by 7 publications

References 30 publications

Prevalence and Pattern of Olanzapine Emergent Obsessive–Compulsive Symptoms: A Cross-sectional Study

Prevalence and Pattern of Olanzapine Emergent Obsessive–Compulsive Symptoms: A Cross-sectional Study

Transcutaneous electrical acupoint stimulation as an adjunct therapy for obsessive-compulsive disorder: A randomized controlled study

Systematic review of environmental risk factors for Obsessive-Compulsive Disorder: A proposed roadmap from association to causation

Contact Info

Product

Resources

About